Nitin Jain: Unraveling Variability in TP53 Aberrant CLL
Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared an article by Anjali Lankford on X:
“ASH!
We know that patients with TP53 aberrant CLL have high risk disease and need treatment sooner than other genomic subgroups such as del13q.But not all TP53 are created equal and there is significant variability in time to first treatment (TTFT).
In this analysis of over 200 pts with TP53 aberrant CLL, we assess what predicts for TTFT within this subgroup.
Work led by Ani Lankford and Mahesh Swaminathan.”
3246 Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia.
Authors: Anjali Lankford, et al.
Dr. Nitin Jain is a Professor of Medicine at The University of Texas MD Anderson Cancer Center, Houston, USA. He leads the CAR T program for the Leukemia Department, MDACC, and received the Leukemia and Lymphoma Society (LLS) Scholar in Clinical Research and Translational Research Program awards in 2022. Specializing in acute and chronic leukemias, notably CLL and ALL, his research focuses on new drug development, reflected in his leadership of multiple investigator-initiated clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023